Volume 29, Number 8—August 2023
Dispatch
Pediatric SARS-CoV-2 Seroprevalence, Oregon, USA, November 1, 2020–June 30, 2022
Rebecca A. Falender, Paul G. Mitchell, Judith A. Guzman-Cottrill, Paul R. Cieslak, and Melissa Sutton
Table
Seroprevalence of SARS-CoV-2 nucleocapsid antibodies in children, Oregon, USA, November 1, 2020–June 30, 2022*
| Collection dates | Sample size | Unadjusted seroprevalence (95% CI) | Adjusted seroprevalence (95% CI) |
|---|---|---|---|
| 2020 Nov 1—Dec 31 | 438 | 0.032 (0.015–0.048) | 0.033 (0.002–0.052) |
| 2021 Oct 1—Oct 3 | 370 | 0.122 (0.090–0.159) | 0.118 (0.090–0.161) |
| 2021 Dec 1—Dec 31 | 278 | 0.137 (0.099–0.183) | 0.134 (0.098–0.184) |
| 2022 Feb 1—Feb 28 | 215 | 0.391 (0.325–0.459) | 0.388 (0.328–0.465) |
| 2022 Apr 1—Apr 30 | 279 | 0.272 (0.221–0.329) | 0.269 (0.222–0.333) |
| 2022 Jun 1—Jun 30 | 289 | 0.301 (0.249–0.358) | 0.298 (0.250–0.362) |
*We calculated adjusted prevalence as observed prevalence + (specificity – 1) divided by sensitivity + (specificity – 1). Adjusted 95% CI obtained with parametric bootstrapping.
Page created: June 22, 2023
Page updated: July 20, 2023
Page reviewed: July 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.